page header

Contents  ·  Introduction  ·  Learning  Objectives  ·  Textbook  ·  Lectures  ·  Procedures  ·  Final Exam  ·  Library  ·  Laboratory  ·  Pharmacy  ·  Imaging  ·  Forms  ·  Videos  ·  About  ·  Contact Us>

Aminophylline (theophylline ethylenediamine) (Truphylline)

Category:

  • Respiratory

Description:

  • Antiasthmatic, bronchodilator, COPD agent

Indications:

  • Asthma, reversible bronchospasm associated with COPD

  • Pulmonary edema

Contraindications:

  • Hypersensitivity to xanthines or ethylenediamine, underlying seizure disorder (not on anticonvulsant therapy)

  • Suppositories contraindicated in presence of infection or irritation of lower bowel or rectum

Precautions:

  • Pregnancy category C

  • Elderly, CHF, corpulmonale, hepatic disease

  • Hypertension, infants <1 year, hypoxemia, sustained high fever, history of peptic ulcer

  • Alcoholism

Adverse Reactions (Side Effects):

  • CNS: anxiety, dizziness, headache, insomnia, lightheadiness, muscle twitching, reflex hyperexcitability, restlessness, seizures

  • CV: circulatory failure, flushing, hypotension, flushing, ventricular arrhythmias

  • GI: anorexia, bitter taste, black stools, diarrhea, dyspepsia, epigastric pain, esophageal reflux, hematemesis, nausea, vomiting

  • GU: proteinuria, urinary frequency

  • MISC: urticaria, alopecia, tachypnea, hyperglycemia

Dosage:

Administered orally, rectally, intravenously

Adult and Child:  

  • PO acute therapy (patient not currently receiving theophylline products): 

    • Following a 6.3 mg/kg loading dose, maintenance dose follows:

      • children age 1-9 years, 5.1 mg/kg every 6 hours 

      • children 9-16 years and smokers, 3.8 mg/kg every 6 hours

      • otherwise healthy non-smoking adults, 3.8 mg/kg every 8 hours

      • older patients/ patients with CHF, corpulmonale, 2.5 mg/kg every 8 hours

  • PO acute therapy (patients currently receiving theophylline products): 

    • Defer loading dose if serum theophylline concentration can be rapidly obtained

    • base loading dose on the principle that each 0.63 mg/kg of aminophylline will increase serum theophylline concentration by 1 mcg/ml 

    • if this is not possible and sufficient respiratory distress is present (without signs of theophylline toxicity), 

      • use 3.1 mg/kg of a rapidly available form of aminophylline

      • will likely increase serum theophylline concentration 5 mcg/ml 

    • maintenance dosage as previously described

  • PO chronic therapy:

    • Initial dose 20.3 mg/kg/24 hours or 500 mg/24 hours (whichever is less) divided by 6-8 hours; 

    • increase every 3 days by 25% as tolerated until clinical response or maximum dose is reached (below); 

    • monitor serum theophylline concentrations; 

    • do not exceed the following (or 1140mg, whichever is less without serum monitoring): 

      • Age 1-9 years, 30.4 mg/kg/day; 

      • age 9-12 years, 25.3 mg/kg/day; 

      • age 12-16 years22.8 mg/kg/day; 

      • age 16 years and older, 16.5 mg/kg/day

  • IV (patients not currently receiving theophylline products): 

    • Following a 6.3 mg/kg IV loading dose, maintenance dose follows: 

      • children age 1-9 years, 1 mg/kg/hr; 

      • children age 9-16 years and smokers, 0.8 mg/kg/hour;  

      • otherwise healthy non-smoking adults, 0.5 mg/kg/hour; 

      • older patients/patients with cor pulmonale 0.3 mg/kg/hour; 

      • patients with CHF, 0.1-0.2 mg/kg/hour

  • IV (patients currently receiving theophylline products): 

    • Defer loading dose if serum theophylline concentration can be rapidly obtained.  

    • Base loading dose on the principle that each 0.63 mg/kg of aminophylline will increase serum theophylline concentration by 1 mcg/ml

    • if this is not possible and sufficient respiratory distress is present:

      • use 3.1 mg/kg aminophylline

      • will likely increase serum theophylline concentration 5 mcg/ml

      • administer only if theophylline toxicity is not present

    • maintenance dosage as described above.

Source: Operational Medicine 2001,  Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300  

Military Obstetrics & Gynecology
© 2003, 2004, 2005, 2006 Medical Education Division, Brookside Associates, Ltd.
All rights reserved

 


This information is provided by The Brookside Associates.  The Brookside Associates, LLC. is a private organization, not affiliated with any governmental agency. The opinions presented here are those of the author and do not necessarily represent the opinions of the Brookside Associates or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. All material presented here is unclassified.

C. 2009, 2014, All Rights Reserved

brookside associates logo

 

 

 

 

 

 

Advertise on this site